Opendata, web and dolomites

NEFERTITI SIGNED

A Novel Eco-Friendly, dually Efficient and Resistance-free Treatment of vaginITIs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NEFERTITI project word cloud

Explore the words cloud of the NEFERTITI project. It provides you a very rough idea of what is the project "NEFERTITI" about.

single    treat    physical    protective    fail    candida    misuse    distributor    natural    pathogenic    repeatedly    counter    curative    alternative    heavy    trials    vvc    biofilms    business    phyph    quality    ph4    adversely    market    life    infected    candidiasis    properly    course    commercial    pessary    levels    misdiagnosis    drug    overconsumption    microorganism    rapid    clinical    worth    vaginal    7bn    vaginosis    caused    recur    lactone    antibiotics    trademarked    once    microbiome    rates    infections    restores    68m    gardnerella    intense    trigger    leads    mark    causative    aerobic    encountering    solution    vcc    commercialisation    resistance    recurrent    bacteria    post    bv    bacterial    socioeconomic    discomfort    compliance    vulvovaginal    self    combination    prescribed    promotes    proliferation    regulatory    lactobacilli    cure    treatments    mucosa    prescription    plan    recurrence    pathogens    antifungals    women    glucono    nefertiti    delta    infection    displaces    fungi    unmatched    disrupts    anaerobic    commercialised    2022    fti    opt    2024    acute    efficacy    form   

Project "NEFERTITI" data sheet

The following table provides information about the project.

Coordinator
GEDEA BIOTECH AB 

Organization address
address: MEDICON VILLAGE SCHEELEVAGEN 2
city: LUND
postcode: 223 81
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 4˙186˙716 €
 EC max contribution 2˙991˙774 € (71%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GEDEA BIOTECH AB SE (LUND) coordinator 1˙970˙073.00
2    LINK MEDICAL RESEARCH AS NO (OSLO) participant 818˙125.00
3    NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST UK (Nottingham) participant 203˙576.00

Map

 Project objective

Bacterial vaginosis (BV) and vulvovaginal candidiasis (VCC) are common vaginal infections caused by Gardnerella and other anaerobic bacteria. or by Candida fungi. The infection can occur once - the acute form - or recur repeatedly over the course of a year. About 68m women in Europe and the US are infected each year. They cause intense physical discomfort, adversely affects quality of life and have heavy socioeconomic costs.

Many women opt to self-treat with non-prescription over-the-counter antifungals which fail because the causative microorganism has not been properly identified. Antibiotics for BV are encountering increasing levels of drug resistance. Combination of misdiagnosis, misuse, non-compliance, overconsumption leads to low efficacy and high recurrence rates for both VVC and BV.

NEFERTITI FTI will demonstrate in clinical trials a pessary based on glucono-δ-lactone –trademarked as pHyph - as a highly effective cure for acute and recurrent BV and VVC, and as a far better alternative to antibiotics or antifungals. pHyph restores the vaginal mucosa to pH4 and disrupts Candida biofilms, promotes the proliferation of natural and protective aerobic lactobacilli, and displaces Gardnerella and other anaerobic pathogenic bacteria. pHyph is a single solution for both pathogens and infections, and with both curative and protective effects, and does not trigger drug resistance in the microbiome. These features are unmatched by any other product on the market – whether as over the counter or prescribed.

NEFERTITI FTI will also develop a post-project business plan for the rapid scale up of production and commercialisation of pHyph in Europe in 2022 as an over-the-counter product into a market for BV and VVC treatments worth €1.7bn in 2022 and will be commercialised through a major drug distributor. The same plan will also mark the regulatory steps and commercial partners needed for pHyph to reach the US market in 2024.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEFERTITI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEFERTITI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

BIOSNAP (2019)

SMART, SUSTAINABLE & CONVENIENT UNIT DOSE PACKAGING

Read More  

GoSafe (2019)

Restoring complete sensory ability for natural walking of amputees

Read More  

GIoT (2019)

Nano-satellites based Global Infrastructure to Enable IoT/M2M Networks - GIoT (Global IoT)

Read More